Educational information only. Not medical advice, not a diagnosis, and not an offer to sell any product. These are experimental or unapproved substances; we do not provide dosage, sourcing, or use guidance. Consult a licensed clinician. We link to official sources only.
A seven-amino-acid synthetic fragment related to the protein thymosin beta-4. Marketed for wound healing and sports recovery. Evidence is largely preclinical.
High demand in male fitness/recovery, frequently compared with BPC-157. Reviewed at the FDA July 2026 compounding meeting.
| Claim | Strongest evidence |
|---|---|
| Wound healing | R Regulatory only |
| Tissue / sports recovery | C Animal |
| Injury repair | C Animal |
FDA proposed a lyophilized powder for injection was reviewed but did not identify human administration data; it flagged injectable immunogenicity, aggregation, impurity, and characterization concerns and proposed not adding it. WADA-relevant.
No human safety/efficacy data identified by FDA. Injectable immunogenicity and impurity concerns. Anti-doping relevance makes athlete use hazardous.
It is a synthetic fragment related to thymosin beta-4, not the full protein.
No. FDA proposed not adding it to the compounding list and did not identify human administration data.
One email when regulatory status changes or strong new evidence lands. Health topics only. Unsubscribe anytime.
Educational information only. Not medical advice, not a diagnosis, and not an offer to sell any product. These are experimental or unapproved substances; we do not provide dosage, sourcing, or use guidance. Consult a licensed clinician. We link to official sources only.